116 related articles for article (PubMed ID: 31686598)
1. Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a
Ming Z; Yongqiang Z; Zijin Z; Yan X; Di C; Xiaoxin T
Pharmacogenomics; 2019 Nov; 20(16):1119-1124. PubMed ID: 31686598
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.
Haroun F; Al-Shaar L; Habib RH; El-Saghir N; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; Cascorbi I; Zgheib NK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):207-14. PubMed ID: 25428516
[TBL] [Abstract][Full Text] [Related]
3. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
4. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
Afsar NA; Ufer M; Haenisch S; Remmler C; Mateen A; Usman A; Ahmed KZ; Ahmad HR; Cascorbi I
Eur J Clin Pharmacol; 2012 Apr; 68(4):389-95. PubMed ID: 22012257
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil.
Jamieson D; Lee J; Cresti N; Jackson R; Griffin M; Sludden J; Verrill M; Boddy AV
Cancer Chemother Pharmacol; 2014 Oct; 74(4):667-74. PubMed ID: 25055937
[TBL] [Abstract][Full Text] [Related]
6. Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.
Hwang M; Medley S; Shakeel F; Vanderwerff B; Zawistowski M; Kidwell KM; Hertz DL
Support Care Cancer; 2022 Sep; 30(9):7355-7363. PubMed ID: 35606478
[TBL] [Abstract][Full Text] [Related]
7. Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma.
Mangó K; Fekete F; Kiss ÁF; Erdős R; Fekete JT; Bűdi T; Bruckner E; Garami M; Micsik T; Monostory K
Sci Rep; 2023 Jul; 13(1):11770. PubMed ID: 37479763
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Helsby N; Yong M; Burns K; Findlay M; Porter D
Cancer Chemother Pharmacol; 2021 Sep; 88(3):533-542. PubMed ID: 34114066
[TBL] [Abstract][Full Text] [Related]
9. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
Ciccacci C; Borgiani P; Ceffa S; Sirianni E; Marazzi MC; Altan AM; Paturzo G; Bramanti P; Novelli G; Palombi L
Pharmacogenomics; 2010 Jan; 11(1):23-31. PubMed ID: 20017669
[TBL] [Abstract][Full Text] [Related]
10. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.
Sládek NE; Kollander R; Sreerama L; Kiang DT
Cancer Chemother Pharmacol; 2002 Apr; 49(4):309-21. PubMed ID: 11914911
[TBL] [Abstract][Full Text] [Related]
11. Association of the CYP2B6 gene with anti-tuberculosis drug-induced hepatotoxicity in a Brazilian Amazon population.
Fernandes DC; Santos NP; Moraes MR; Braga AC; Silva CA; Ribeiro-dos-Santos A; Santos S
Int J Infect Dis; 2015 Apr; 33():28-31. PubMed ID: 25271170
[TBL] [Abstract][Full Text] [Related]
12. The role of polymorphic cytochrome P450 gene (CYP2B6) in B-chronic lymphocytic leukemia (B-CLL) incidence and outcome among Egyptian patients.
Al-Adl M; Youssef MM; El-Sebaie A; Refaat S; El-Said A
Oncol Res; 2024; 32(4):785-797. PubMed ID: 38560574
[TBL] [Abstract][Full Text] [Related]
13. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
Zhou X; Wang X; Song Q; Yang H; Zhu X; Yu J; Song G; Di L; Ren J; Shao H; Lyerly HK
Int J Clin Pharmacol Ther; 2015 Nov; 53(11):914-22. PubMed ID: 26396136
[TBL] [Abstract][Full Text] [Related]
14. Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.
Afsar NA; Haenisch S; Mateen A; Usman A; Ufer M; Ahmed KZ; Ahmad HR; Cascorbi I
Basic Clin Pharmacol Toxicol; 2010 Jul; 107(1):570-6. PubMed ID: 20102361
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M; Komagata S; Fujiki Y; Kanada Y; Ebi H; Itoh K; Mukai H; Yokoi T; Minami H
Pharmacogenet Genomics; 2007 Jun; 17(6):431-45. PubMed ID: 17502835
[TBL] [Abstract][Full Text] [Related]
16. CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Int J Antimicrob Agents; 2014 Mar; 43(3):292-6. PubMed ID: 24359841
[TBL] [Abstract][Full Text] [Related]
17. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
Low SK; Kiyotani K; Mushiroda T; Daigo Y; Nakamura Y; Zembutsu H
J Hum Genet; 2009 Oct; 54(10):564-71. PubMed ID: 19696793
[TBL] [Abstract][Full Text] [Related]
18. The mechanism and risk factors of clopidogrel-induced liver injury.
Zhai Y; Wang L; Yang F; Feng G; Feng S; Cui T; An L; He X
Drug Chem Toxicol; 2016 Oct; 39(4):367-74. PubMed ID: 26654298
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of CYP2B6 polymorphisms in Argentinians: the role of genetic testing.
Scibona P; Vazquez C; Cajal AR; Argibay PF; Belloso WH
Genet Mol Res; 2015 Dec; 14(4):16594-9. PubMed ID: 26681005
[TBL] [Abstract][Full Text] [Related]
20. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Helsby NA; Yong M; van Kan M; de Zoysa JR; Burns KE
Br J Clin Pharmacol; 2019 Sep; 85(9):1925-1934. PubMed ID: 31218720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
